1 completed, 1 terminated, 1 withdrawn. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow Carcinoma of Esophagus: new trials by email Literature Review of Carcinoma of Esophagus trials Research Report on Carcinoma of Esophagus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs Stage III Breast Cancer, Stage IV Breast Cancer | Withdrawn | Travera Inc | 2024-11-01 | 2024-11-25 | ||
| Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) Pleural Effusion, Malignant, Ascites, Malignant | Completed | Travera Inc | 72 | 2022-07-15 | 2026-04-13 | |
| Pre-op Chemo-RT w/CDDP/5FU vs Chemo w/ Docetaxel/Irinotecan in PET Non Responder Resectable Esophagus Cancer irinotecan and docetaxel, Cisplatin, fluorouracil and concurrent radiation therapy - Carcinoma of Esophagus | Phase 2 | Terminated | King Faisal Specialist Hospital & Research Center | 170 | 2012-05-01 | 2018-08-10 |
Esophageal Neoplasms (3) · Anus Neoplasms (2) · Appendiceal Neoplasms (2) · Breast Neoplasms (2) · Carcinoma (2) · Carcinoma, Hepatocellular (2) · Carcinoma, Neuroendocrine (2) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Cholangiocarcinoma (2) · Laryngeal Neoplasms (2) · Lung Neoplasms (2) · Mesothelioma (2) · Mouth Neoplasms (2) · Neoplasms, Unknown Primary (2)
Digestive System Diseases (3) · Digestive System Neoplasms (3) · Esophageal Diseases (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Head and Neck Neoplasms (3) · Neoplasms (3) · Neoplasms by Site (3) · Adenocarcinoma (2) · Adenoma (2) · Adnexal Diseases (2) · Anus Diseases (2) · Breast Diseases (2) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2)
Cisplatin (1) · Docetaxel (1) · Fluorouracil (1) · Irinotecan (1)
Travera Inc (2) · King Faisal Specialist Hospital & Research Center (1)
Saudi Arabia (1) · United States (1)
Mark Stevens, Ph.D. (1) · Mark Stevens, Phd (1) · Rob Kimmerling, Phd (1) · Robert Kimmerling, Ph.D. (1) · Shouki Bazarbashi, MD (1)